KURA ONCOLOGY INC. - COMMON STOCK

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer

28 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in Cantor Global Healthcare Conference 2023

19 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

14 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Second Quarter 2023 Financial Results

03 Aug 2023 16:05:03 By Nasdaq GlobeNewswire

Kura Oncology to Report Second Quarter 2023 Financial Results

27 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

14 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Kura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants

13 Jun 2023 16:01:00 By Nasdaq GlobeNewswire

Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress

11 Jun 2023 03:45:00 By Nasdaq GlobeNewswire

Kura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress

30 May 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in Two Upcoming Investor Conferences

23 May 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports First Quarter 2023 Financial Results

10 May 2023 16:03:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in JMP Securities Life Sciences Conference

09 May 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Report First Quarter 2023 Financial Results

03 May 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology to Participate in Stifel Targeted Oncology Days

18 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies

17 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting

14 Mar 2023 17:32:53 By Nasdaq GlobeNewswire

Kura Oncology to Participate in Upcoming Investor Conferences

01 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

23 Feb 2023 16:03:00 By Nasdaq GlobeNewswire

Kura Oncology to Report Fourth Quarter and Full Year 2022 Financial Results

16 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Kura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

09 Feb 2023 07:30:00 By Nasdaq GlobeNewswire